🔴 Aquestive Therapeutics is trading 5% down today after wider-than-expected Q2 loss

Aquestive Therapeutics is trading 5% down now at $4.04 after investors continued weighing its August 11 earnings.

• Second-quarter revenue increased 38% year over year, but the company reported a wider-than-expected $0.18-per-share loss, partly reflecting an $11.7 million debt-extinguishment charge.
• Coverage highlighted cash-burn concerns and a softer outlook around Anaphylm’s launch timeline.
• The decline appears company-specific; major U.S. indices were modestly higher during the August 14 session. Aquestive remains on track to resubmit Anaphylm’s NDA in Q3 2026.